Peripheral blood stem cells collection by apheresis in very low‐weight children with malignant diseases—A single center experience. Issue 1 (9th October 2022)

• Record Type: Journal Article
• Authors: Vieira, Lúcia; Teixeira, Sofia; Reis, Conceição; Salselas, Ana; Bordalo, Filipa; Lopes, Sérgio; Pinho, Catarina; Amado, Fátima; Roncon, Susana
• Is Part Of: Journal of clinical apheresis. Volume 38:Issue 1(2023)
• Page Start: 24
• Page End: 32
• Publication Date: 2022-10-09
• Subjects: cellular therapy -- extracorporeal blood volume -- hematopoietic stem cells -- leukocytapheresis -- malignant disease -- pediatric patients -- very low body weight; Hemapheresis -- Periodicals; Blood -- Transfusion -- Periodicals; Blood -- Transfusion, Autologous -- Periodicals; Cell separation -- Periodicals; Leukapheresis -- Periodicals; Plasmapheresis -- Periodicals; 615.39
• DOI: 10.1002/jca.22021
• Languages: English
• ISSNs: 0733-2459

Abstract

Abstract: Background: Hematopoietic stem cell transplantation is used in the treatment of children with malignant and non‐malignant diseases. However, apheresis of peripheral blood stem cells (PBSC) represents a challenge in children below 10 kg. Methods: A retrospective trial was conducted in the Cellular Therapy Department of Portuguese Oncology Institute of Porto. Inclusion criteria: children with body weight inferior to 10 kg who underwent autologous PBSC apheresis until 2021. Demographic and clinical data were collected and our institutional protocol was described. COBE Spectra apheresis system (TerumoBCT, Lakewood, Colorado) until 2012 and then Spectra Optia (TerumoBCT) were used. Results: Sixteen leukocytaphereses were performed in 13 patients—nine females (69%). Mean age and weight were 13.31 months (±5.26) and 8.31 kg (±1.17), respectively. The initial CD34+ cells/μL in peripheral blood was 70.8 (±61.9). A central venous catheter (CVC) was exclusively used in all but one patient, in whom a peripheral vein was also required. In 10 procedures, both heparin and anticoagulant citrate dextrose solution—formula A (ACD‐A) were used; in the remaining ones, only ACD‐A was employed. The median duration of each procedure was 168 minutes (±45) and 2.96 blood volumes (±0.31) were processed. Median CD34+ cells yield per leukocytapheresis was 6.52 × 10 6 /kg (±9.87 × 10 6 ). CD34+ cell extraction rates were not significantly different between the two apheresis systems. Platelet and magnesium levels were significantly lower after collection ( P < .001 and P = .009, respectively). Conclusions: Although recommendations are lacking, we have successfully and safely performed leukocytaphereses in children with body weight below 10 kg. The authors believe that a permanent and dynamic comprehensive evaluation of each child is paramount for attaining good results.